Objective: Inhaled nitric oxide (iNO) use in infants >1500 g, but <34 weeks gestation with severe respiratory failure will reduce the incidence of death and/or bronchopulmonary dysplasia (BPD).
Introduction
Survival and outcome in the premature infant with severe respiratory failure is limited by respiratory distress syndrome (RDS) and its sequela, bronchopulmonary dysplasia (BPD).
1,2 Inhaled nitric oxide (iNO) has been shown in term and near-term infants >34 weeks gestation and >2 kg to improve acutely oxygenation and decrease the need for extracorporeal membrane oxygenation (ECMO). 3, 4 One trial reported a lower rate of BPD in the iNO-treated group. 4 Until recently, the effects of iNO on vascular tone and ventilation perfusion matching were assumed to be responsible for its benefit, 5 but recent animal model investigation has shown that deficient endogenous NO disrupts pulmonary parenchymal and vascular development and that exogenous NO may benefit the developing lung by its effects on vascular remodeling, inflammation and pulmonary edema, lung mechanics, lung growth, angiogenesis and airway smooth muscle. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Despite these intriguing animal model findings, the benefit of iNO in premature infants has not been consistently demonstrated in randomized clinical trials. Several small trials demonstrated an increase in oxygenation with iNO therapy, but no significant impact on the primary endpoints of death and/or BPD was demonstrated. [18] [19] [20] [21] [22] Recent large clinical trials have shown varying results with significant differences in study design, entry criteria and duration of iNO use. [23] [24] [25] Schreiber et al. 23 demonstrated a significant decrease in BPD and/or death with iNO use in infants requiring mechanical ventilation and surfactant, but surprisingly no benefit was seen in infants with an oxygenation index (OI) greater than 6.94. Infants >1500 g treated with iNO had a higher rate of survival without BPD (100% vs 83%), but there were only 27 infants in this birth weight subgroup. A trial performed by the National Institute of Child Health and Development (NICHD) Neonatal Research Network of iNO use in critically ill infants <1500 g with a mean OI of approximately 20 showed no decrease in BPD and/or death. However, post hoc analysis suggested increased survival and/or decreased BPD for those infants >1000 g. 24 The NICHD and Schreiber trials differed in several trial design issues; the Schreiber trial had a lower severity of illness as measured by the OI, a lower use of antenatal steroids, a higher percentage of black infants enrolled, and was performed at a single site. Most recently, a large randomized trial performed by Kinsella and co-workers enrolled 793 infants <1250 g requiring mechanical ventilation and failed to demonstrate a decrease in BPD and/or death with iNO therapy, but again, subgroup analysis suggested reduction in BPD for those infants 1000 to 1250 g receiving iNO. 25 Unlike previous trials, Ballard and co-workers investigated the use of iNO therapy in infants with established BPD at 7 to 21 days of age.
A pilot study of iNO use in larger preterm infants with birth weight >1500 g but <34 weeks was performed concurrently with the NICHD trial. Pilot data collection done in NICHD Neonatal Network centers had established that there would be low numbers of infants in this weight range. Concurrent collection of randomized data for this weight group was seen as desirable despite the likelihood that there would be insufficient power.
Methods

Hypotheses and outcomes
The primary hypothesis was that administration of iNO to neonates >1500 g, but <34 weeks with severe respiratory failure would reduce the incidence of BPD and/or death. Severe respiratory failure was defined as an OI of 15 or more on two consecutive measurements of arterial blood gases (ABGs) between 30 min and 12 h apart. Death was defined as death before discharge to home or within 365 days in hospitalized infants. BPD was defined as the use of oxygen at 36 weeks post-menstrual age.
We also examined the incidence of grade 3 or 4 intraventricular hemorrhage (IVH) or periventricular leukomalacia (PVL), physiologic BPD, threshold retinopathy of prematurity (ROP), the number of days of assisted ventilation, oxygen use and hospitalization, and the rate of the combined outcome of death and/or neurodevelopmental impairment (NDI) at 18 to 22 months of age adjusted for prematurity. The rates of severe IVH or PVL were based on local radiology readings of the worst results among ultrasound examinations performed during administration of study gas, at 28±3 days, and after 28 days of age. Physiologic BPD was determined as described by Walsh et al. 26 NDI was defined as moderate to severe cerebral palsy (CP), bilateral blindness (no useful vision in either eye) or deafness (requiring hearing aids in both ears), or Bayley Scales of Infant Developmental Index (BSID) II Mental Developmental Index (MDI) or Psychomotor Developmental Index (PDI) <70 at 18 to 22 months adjusted for prematurity.
Eligibility criteria
Infants <34 weeks gestation, by best obstetric estimate, and weighing >1500 g who required mechanical ventilation with a diagnosis of RDS, sepsis and/or pneumonia, aspiration syndromes, idiopathic pulmonary hypertension or suspected pulmonary hypoplasia were eligible. Eligible infants had received at least one dose of surfactant 4 h before meeting the respiratory entry criteria of OI X15 on two consecutive ABGs between 30 min and 12 h apart. At the first scheduled interim analysis, the Data Safety and Monitoring Committee (DSMC) noted a higher mortality rate than expected in both treatment groups and requested that the entry criteria be modified. The OI criteria were revised to an OI X10 followed by an OI X12.5 within 30 min to 24 h. For the purpose of analysis, the design was considered to have two strata based on the OI entry criteria. Infants were ineligible if they had congenital heart disease, thrombocytopenia defined as a platelet count p50 000/ml), bleeding diathesis or if a decision had been made not to provide full treatment. Each study center obtained institutional review board approval, and written informed consent was obtained from parents or guardians.
Randomization and masking
Infants were randomized using a dedicated telephone system developed by the data center. Infants were stratified according to center with a permuted block design. Randomization, study gas administration and safety monitoring were performed by designated, unmasked individuals not involved in clinical care. To maintain masking, they made mock adjustments in the control infants, used an INOvent (INOvent, Datex-Ohmeda, Madison, WI, USA) with a specially designed gauge cover secured with a numbered tether, used a oxygen analyzer upstream of the study gas administration site, and covered the downstream oxygen analyzer. A shroud secured with tamper sensitive tape was used to cover the tank label and a screen was used to ensure masking when the INOvent gauge cover was opened. All other research and clinical personnel were masked to the treatment assignment.
Administration of study gas The study protocol was based on previous iNO trials performed by the Neonatal Research Network. 3, 27 Research personnel collected demographic, perinatal and infant data including morbidities and treatments at each center using common definitions. Mode of ventilation was not dictated by the study protocol, nor was it a randomization factor. Study gas was initiated at 5 ppm and could be increased to 10 ppm, with escalation and weaning criteria defined by the study protocol. 24 The maximum study gas exposure was 14 days.
Neurodevelopmental follow-up Neurodevelopmental follow-up was required in the initial study protocol. Death and/or NDI at 18 to 22 months of age corrected for prematurity and other neurodevelopmental outcomes including components of NDI were examined.
Statistical analysis
Data were analyzed based on the intent-to-treat principle. Differences between the treatment groups in baseline characteristics, status at randomization and response to study gas were tested using t-tests for continuous variables and w 2 tests for iNO use in the >1500 g premature infant KP Van Meurs et al categorical variables. Owing to non-normal distributions, Wilcoxon tests were used for number of surfactant doses, length of hospital stay and duration of ventilation. Adjusted differences in the primary and secondary outcomes were tested using the Cochran-Mantel-Haenszel Test controlling for OI stratum. Cochran-Mantel-Haenszel statistics were used to calculate the adjusted relative risks (RRs) and 95% confidence limits. 28 This pilot was planned to terminate when the main trial concluded. INO Therapeutics provided study gas, gas delivery systems and site monitoring for all hospitals, as well as capitation funding for the hospitals that were not members of the NICHD Neonatal Research Network. INO Therapeutics was not involved in the study design, data analysis and interpretation, or paper preparation.
Results
Between 4 January 2001 and 26
September 2003, 29 infants were enrolled in this trial. 15 were enrolled in the first OI entry strata and 14 in the second OI strata. The main trial was terminated on 26 September 2003 at the recommendation of the Data Safety and Monitoring Committee following the second planned interim analysis with two-thirds of the enrolled infants at a study end point found the incidence of grade 3 or 4 IVH or PVL was significantly higher in the group receiving iNO than in the control group. Enrollment in the current trial concluded at this time.
Baseline characteristics and status at randomization There were no statistically significant differences between the treatment groups in the initial baseline characteristics ( Table 1) . The mean age at randomization was approximately 24 h and the mean OI was approximately 25. The status at randomization differed in that the control group was more likely to have been managed with high-frequency ventilation at study entry (P<0.03) ( Table 2 ). There were no other differences in the status at randomization between the treatment groups.
Primary and secondary outcomes There were no significant differences in the composite outcome of BPD and/or death, death, or BPD, between the iNO and control groups, respectively without adjustment (Table 3) . With adjustments for OI entry strata, there were no differences in death and/or BPD, death or BPD. It should be noted that adjusted RRs for a number of outcomes could not be obtained as the adjusted models did not converge owing to sample size limitations.
There were no statistically significant differences between the groups in any of the secondary outcomes examined (Table 3) . Thirty minutes following the administration of 5 ppm study gas, the iNO group had a significant increase in PaO 2 and a significant decrease in the OI when compared to controls (Table 4) . There was not a significant change in PaO 2 or OI in either group when the concentration of study gas was increased to 10 ppm.
In the iNO or control group, no infant had methemoglobin X4% or NO 2 levels X3 ppm. There were three deviations from the protocol. Three infants received open-label iNO, two who had been assigned to the control group and one who had been a nonresponder in the iNO group.
Of the 29 patients enrolled, five (36%) of the iNO group and four (27%) of the control group died before discharge. All of the nine survivors in the iNO group and eight of the 11 survivors in the control group (73%) were available for followup. Thus, the rate of death and/or NDI could be determined for 100% of the iNO group and 80% of the control group. There were no differences between the iNO and control groups for the composite outcome of death and/or NDI (Table 5) . With adjustment for OI entry strata, there were no differences in neurodevelopmental outcomes examined at 18 to 22 months. All cases of NDI were explained by cognitive impairment (MDI <70); no child in either treatment group was diagnosed with other components of NDI. 
Discussion
In this small pilot trial of iNO use in infants >1500 g and <34 weeks gestation with severe respiratory failure, there was no significant decrease in the rate of death and/or BPD after adjustment for OI entry strata. This information should be considered in context of the results of the large randomized clinical trials of early iNO use in premature infants available. Little information is available on the use of iNO in infants >1500 g and <34 weeks. The Schreiber trial reported a reduction in BPD and/or death in infants <34 weeks requiring mechanical ventilation. Subgroup analysis by birth weight for infants >1500 g (n ¼ 27) showed higher survival in the iNO-treated group (100% vs 83%). Both the NICHD Neonatal Research Network and Kinsella trials found no reduction in death and/or BPD in the main trials despite significant differences in trial design, but subgroup analysis by birth weight in both trials suggested that infants with birth weight >1000 g may benefit with decreased BPD and/or death. In the NICHD trial, 25 a significant interaction of treatment and birth weight on outcome was seen (P ¼ 0.02). Infants p1000 g (n ¼ 316) had increased rates of BPD and/or death when treated with iNO, as well as increased rates of severe intracranial hemorrhage or PVL while infants >1000 g (n ¼ 104) had a statistically significant reduction in BPD and/or death when treated with iNO (50% vs 69%, RR 0.72, 95% confidence interval (CI) 0.54 to 0.96, P ¼ 0.03). In the Kinsella trial, 24 a significant interaction (<0.001) between birth weight strata and treatment was also found. Infants in the birth weight strata of 1000 to 1250 g (n ¼ 129) treated with iNO had significant reductions in the combined end point of death and/or BPD (P ¼ 0.004) as well as in BPD (P ¼ 0.001). Of interest is the lower rate of neurologic injury seen in the iNO group in the Schreiber and Kinsella trials. 23, 25 Mestan et al. 29 also reported a potential neuroprotective effect of iNO in their follow-up study with improved neurodevelopmental outcome seen in the iNO group due to a decrease in the rate of cognitive impairment defined as Bayley MDI <70 (P ¼ 0.03). The neurodevelopmental outcome of the 29 infants reported here did not detect any difference in the rate of NDI, but it was not higher as suggested in the follow-up performed for the main trial by Hintz et al.
30
There are several limitations to this analysis. The main limitation is the small size of the pilot cohort (n ¼ 29). Screening performed for the PiNO trial in NICHD centers had suggested that the number of babies >1500 g meeting the OI entry criteria would be low. A decision was made to enter infants >1500 g in a parallel pilot and require a higher OI for entry to attempt to match severity of illness with the main trial. Another limitation may have been the manner in which iNO was administered. As suggested by Kinsella et al.
14 the benefit of iNO on perinatal lung development may require a longer duration of use. This trial used iNO for a short duration, and was discontinued in infants without an improvement in oxygenation following initiation of iNO.
The severity of illness as measured by OI for this cohort of 29 infants >1500 g, but <34 weeks is notable. The mean OI for the iNO group is 25 and for the control group is 28. Although 420 infants <1500 g were entered in the main trial over a period of 2 years and 9 months, only 29 infants >1500 g were enrolled over the same time period in this trial. We may conclude that the incidence of severe respiratory failure unresponsive to surfactant and routine intensive care is uncommon in this birth weight group. For this reason, trials of iNO use as a rescue therapy for premature infants >1500 g and <34 weeks with severe respiratory failure will be difficult to perform.
In conclusion, this pilot trial of iNO use in infants >1500 g and <34 weeks gestation with severe respiratory failure demonstrated no significant decrease in the death and/or BPD after adjustment for OI entry strata. Sample size limitations hinder definitive conclusions regarding benefit from iNO treatment for these infants.
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